Clinical trials: Type A Botulinum Toxin
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
The purpose of this study is to explore the effectiveness and safety of several doses of botulinum toxin type A in treating overactive bladder in patients with spinal cord injury.
- Trial name
- NCT00575016
- Testing
- botulinum toxin Type A (50U); botulinum toxin Type A (200U), botulinum toxin Type A (100U); botulinum toxin Type A (200U), botulinum toxin Type A (200U)
- Where
- 6 sites in Egypt, Greece and 4 more
- Volunteers
- 74 people
- Sponsor
- Allergan
Wrinkles in Frontal Area
Comparison of Two Commercial Preparations of Botulinum Toxin Type A
The objective of this study is to compare the action halos of the botulinum toxins (Dysport® and Botox®) using two equivalence-ratios and to gather supportive information, such as more detailed data on the effectiveness in…
- Trial name
- NCT00959907
- Testing
- BOTULINUM TOXIN TYPE-A
- Where
- Brazil
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Hexsel Dermatology Clinic
Stroke With Hemiparesis
Study of Botulinum Toxin and Recovery of Hand Function After Stroke
The purpose of this study is to determine whether injections of botulinum toxin (commonly known as BOTOX®) into the affected hand of Stroke patients, while targeting the muscles controlling the hand, will lead to improved use of…
- Trial name
- NCT01422161
- Testing
- Botulinum Toxin commonly known as BOTOX®
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- NYU Langone Health
Spasmodic Torticollis
Comparison of Efficacy and Safety of Two Different Types of Botulinum Toxin Type A in Moderate to Severe Cervical Dystonia
The purpose of this study is to compare two types of botulinum toxin type A to treat the involuntary muscle contractions in the neck
- Trial name
- NCT00528541
- Testing
- botulinum toxin type A
- Where
- 5 sites in Australia, Croatia and 3 more
- Volunteers
- 145 people
- Sponsor
- Allergan
Glabellar Frown Lines
Study to Demonstrate Safety and Duration of Effect of 40 Units of PrabotulinumtoxinA-xvfs to Treat Glabellar Lines
The purpose of this study is to demonstrate the safety and duration of effect of 40 Units of prabotulinumtoxinA-xvfs (Jeuveau®) in providing temporary improvement in the appearance of moderate to severe glabellar lines (frown…
- Trial name
- NCT05320393
- Testing
- PrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA
- Where
- United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Evolus, Inc.
Restless Legs Syndrome
Botulinum Toxin to Treat Restless Legs Syndrome
This study will test whether botulinum toxin (Botox) may relieve the uncomfortable sensations patients with restless legs syndrome (RLS) experience.
- Trial name
- NCT00479154
- Testing
- Botulinum Toxin A
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Urinary Urge Incontinence
Efficacy of Botulinum Toxin Type A for the Treatment of Non-neurogenic Urinary Urge Incontinence
Non-neurogenic urinary urge incontinence (UUI) is a common quality of life disorder that causes people to feel an "urgent" need to urinate.
- Trial name
- NCT01226706
- Testing
- Botulinum Toxins, Type A
- Where
- Canada
- Volunteers
- 21 people
- Sponsor
- Saskatchewan Health Authority - Regina Area
Overactive Bladder
Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
- Trial name
- NCT00910520
- Testing
- onabotulinumtoxinA, normal saline
- Where
- 7 sites in United States, Belgium and 5 more
- Volunteers
- 548 people
- Sponsor
- Allergan
Masseter Muscle Hypertrophy
Botulinum Toxin Type A (BOTOX®) Treatment of Masseter Muscle Hypertrophy
This study will evaluate the safety and efficacy of a range of doses of botulinum toxin Type A (BOTOX®) for the treatment of patients with bilateral Masseter Muscle Hypertrophy (MMH).
- Trial name
- NCT02010775
- Testing
- botulinum toxin Type A, Normal saline
- Where
- 14 sites in Australia, Canada and 1 more
- Volunteers
- 187 people
- Sponsor
- Allergan
Dyssynergic Defaecation, Evacuation Disorder
Infracoccygeal Botox for Dyssynergia
Background: Constipation is a common problem, affecting up to 20% of the population during their lifetime. Some patients respond poorly to standard treatments such as laxatives.
- Conditions
- Dyssynergic Defaecation, Evacuation Disorder, Anismus, Defecation Disorder
- Trial name
- NCT04879524
- Testing
- Percutaneous infracoccygeal Botulinum toxin injection to puborectalis
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Queen Mary University of London
Cervical Dystonia
Botox for Cervical Dystonia Following EMG Mapping
The purpose of this study is to determine how to improve treatment of patients with cervical dystonia who have not been helped with standard Botox injections.
- Trial name
- NCT00773253
- Testing
- Botulinum toxin A
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Scleroderma, Raynaud's Syndrome
Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome
This is a randomized, double-blinded, clinical trial assessing the therapeutic efficacy of Botulinum toxin A (Onabotulinumtoxin A) in treating scleroderma-associated Raynaud's syndrome.
- Trial name
- NCT02165111
- Testing
- Onabotulinumtoxin A, sterile saline solution
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Johns Hopkins University
Parkinson's Disease, Neurogenic Bladder
Safety and Efficacy of botulinumA Toxin (BotoxA) for Treatment of Neurogenic Bladder of Parkinson's Disease
The basic nerve deficit of Parkinson's disease (PD) leads to lower urinary tract symptoms of frequency, urgency and urge urinary incontinence. Lower urinary tract symptoms tend to occur at more advanced stages of PD.
- Conditions
- Parkinson's Disease, Neurogenic Bladder, Urinary Incontinence, Clostridium Botulinum Toxin Adverse Reaction
- Trial name
- NCT01421719
- Testing
- Cystoscopic injection of Botox into the urinary bladder
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Stanford University
Depression
The Treatment of Depression With Botulinum Type A Toxin
A 24-week Randomized, Double-blind study treating people who suffer from depression who also have moderate to severe frown lines in forehead region with Botox injections.
- Trial name
- NCT01392963
- Testing
- botulinum toxin type A neurotoxin complex
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Seton Healthcare Family
Platysma Prominence
A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence
This is a Phase 3, open-label extension study to evaluate the long-term safety of repeat BOTOX treatments in adult participants with Platysma Prominence.
- Trial name
- NCT05134649
- Testing
- OnabotulinumtoxinA
- Where
- 29 sites in United States, Canada
- Volunteers
- 292 people
- Sponsor
- AbbVie
Smiling, Botulinum Toxins, Type A
Higher Doses of Botulinum Toxin in the Treatment of Gummy Smile
Botulinum type A (BTX-A) is an easy and efficacious treatment for gingival smile (GS). However, the necessary for higher-doses among patients are controversial.
- Trial name
- NCT05127018
- Testing
- injection of Botulinum type A
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Peking University
Episodic Migraine
Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound (International Classification of Headache Disorders, 2018).
- Trial name
- NCT05028569
- Testing
- BOTOX
- Where
- 133 sites in United States, Canada and 7 more
- Volunteers
- 775 people
- Sponsor
- AbbVie
Bruxism, Temporomandibular Disorders (TMD)
Short-Term Symptom Changes in Adults With Teeth Clenching or Grinding and Jaw Symptoms Receiving Splint, Botulinum Toxin, or Medication Plus Splint Care
This prospective observational study evaluated short-term patient-reported symptom changes in adults with bruxism-related and temporomandibular disorder symptoms who received one of three clinically selected management…
- Conditions
- Bruxism, Temporomandibular Disorders (TMD), Myofascial Pain
- Trial name
- NCT07586072
- Testing
- Occlusal splint, Botulinum Toxin Type A (Dysport®), Thiocolchicoside
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Recep Tayyip Erdogan University
Overactive Bladder
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.
- Trial name
- NCT00439140
- Testing
- botulinum toxin Type A
- Where
- 4 sites in United States, Australia and 2 more
- Volunteers
- 41 people
- Sponsor
- Allergan
Depression, Quality of Life
Quality of Life and Self-esteem After Botox® Injections in Depressed and Non-depressed Patients
The primary objective of this study is to determine the alterations in quality of life and self-esteem after BOTOX® injections in the glabella in depressed and non-depressed patients.
- Trial name
- NCT01004042
- Testing
- Botulinum Toxin Type A
- Where
- Brazil
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Hexsel Dermatology Clinic